Evotec Signs an Agreement with Sanofi for Novel Drug Development

 Evotec Signs an Agreement with Sanofi for Novel Drug Development

Evotec Signs a Research Agreement with Indivumed to Develop Precision Therapies for Colorectal Cancer (CRC)

Shots:

  • Sanofi and Evotec launches BRIDGE LAB031, designed to convert academic research into drug discovery candidates for multiple therapeutic areas. BRIDGE is a public-private partnership combining academia, biotech and venture capital into pharma for early-stage projects
  • The companies will focus on development of multiple small molecule programmes through lead optimization for next three years
  • Evotec will develop and generate multiple lead candidates for Sanofi and apply its technologies to the projects for expedited drug discovery and development. Sanofi has an option to acquire development rights of products on expected milestone criteria

Click here to read full press release/ article | Ref: Evotec | Image: Handelsblatt

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post